Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: Results from a randomised trial

British Journal of Cancer

Volumn 104, Issue 6, 2011, Pages 899-902

  Rosell, J ^a,b   Nordenskjold B ^b   Bengtsson, N O ^c   Fornander, T ^d   Hatschek, T ^d   Lindman, H ^e   Malmstrom P O ^f   Wallgren, A ^g   Stal O ^b   Carstensen, J ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

adjuvant treatment; adverse events; breast cancer; cerebrovascular disease; tamoxifen

Indexed keywords

TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BRAIN ISCHEMIA; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CEREBROVASCULAR DISORDERS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SWEDEN; TAMOXIFEN; TIME FACTORS;

EID: 79952696979     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.45     Document Type: Article

References (13)

1. ATAC Trialists' Group (2008) Effect of anastroloze and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45-53
2. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18: 937-947 (Pubitemid 37510624)
3. Bushnell CD, Goldstein LB (2004) Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 63: 1230-1233 (Pubitemid 39350022)
4. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN (2001) Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 21: 255-261 (Pubitemid 32125375)
5. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A (2007) Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99: 272-282 (Pubitemid 47073490)
6. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet 365: 1687-1717
7. Magliano D, Rogers S, Abramson M, Tonkin A (2006) Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 113: 5-14
8. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. BMJ 311: 977-980
9. Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L (2009) Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 151: 703-715
10. Nilsson AC, Spetz CL, Carsjo K, Nightingale R, Smedby B (1994) Reliability of the hospital registry. The diagnostic data are better than their reputation. Läkartidningen 91: 598, 603-605. In Swedish
11. Nordenskjöld B, Rosell J, Rutqvist LE, Malmström PO, Bergh J, Bengtsson NO, Hatschek T, Wallgren A, Carstensen J (2005) Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 97: 1609-1610 (Pubitemid 41662715)
12. Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543-1549
13. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27: 3235-3258